📊 CDLX Key Takeaways
Investment Thesis
Cardlytics exhibits severe financial distress with negative stockholders' equity of -6.5M, indicating liabilities exceed assets. Despite 9.9% revenue growth, the company is deeply unprofitable with a -44.4% net margin and -101.8M operating loss, burning cash despite positive operating cash flow. The combination of negative equity, massive long-term debt of 212.6M, and inability to achieve profitability presents substantial solvency risk.
CDLX Strengths
- Revenue growth of 9.9% year-over-year demonstrates demand for services
- Positive operating cash flow of 9.3M and free cash flow of 8.8M provide near-term liquidity buffer
- Current ratio of 1.75x indicates adequate short-term liquidity to meet immediate obligations
CDLX Risks
- Negative stockholders' equity of -6.5M signals balance sheet insolvency and technical bankruptcy
- Operating margin of -43.6% and net margin of -44.4% indicate fundamental business model issues with losses on every dollar of revenue
- Long-term debt of 212.6M against only 285.6M total assets creates high leverage and refinancing risk, especially given inability to generate profits
- Net loss of 103.5M despite revenue growth demonstrates deteriorating operational performance regardless of top-line expansion
Key Metrics to Watch
- Path to operating profitability and improvement in operating margin trajectory
- Total liabilities relative to assets to monitor solvency and negative equity trend
- Operating cash flow sustainability and burn rate relative to cash reserves
CDLX Financial Metrics
💡 AI Analyst Insight
The relatively thin 3.8% FCF margin may limit capital allocation flexibility.
CDLX Profitability Ratios
CDLX vs Technology Sector
How Cardlytics, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CDLX Balance Sheet & Liquidity
CDLX 5-Year Financial Trend
5-Year Trend Summary: Cardlytics, Inc.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.69 indicates the company is currently unprofitable.
CDLX Growth Metrics (YoY)
CDLX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $47.0M | -$72.7M | $-1.36 |
| Q2 2025 | $58.0M | -$4.3M | $-0.09 |
| Q1 2025 | $56.4M | -$13.3M | $-0.26 |
| Q3 2024 | $61.1M | -$24.0M | $-0.63 |
| Q2 2024 | $64.0M | -$4.3M | $-0.09 |
| Q1 2024 | $59.0M | $13.6M | $0.40 |
| Q3 2023 | $67.3M | $6.3M | $0.19 |
| Q2 2023 | $69.3M | -$9.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CDLX Capital Allocation
CDLX SEC Filings
Access official SEC EDGAR filings for Cardlytics, Inc. (CIK: 0001666071)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CDLX
What is the AI rating for CDLX?
Cardlytics, Inc. (CDLX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CDLX's key strengths?
Revenue growth of 9.9% year-over-year demonstrates demand for services. Positive operating cash flow of 9.3M and free cash flow of 8.8M provide near-term liquidity buffer.
What are the risks of investing in CDLX?
Negative stockholders' equity of -6.5M signals balance sheet insolvency and technical bankruptcy. Operating margin of -43.6% and net margin of -44.4% indicate fundamental business model issues with losses on every dollar of revenue.
What is CDLX's revenue and growth?
Cardlytics, Inc. reported revenue of $233.3M.
Does CDLX pay dividends?
Cardlytics, Inc. does not currently pay dividends.
Where can I find CDLX SEC filings?
Official SEC filings for Cardlytics, Inc. (CIK: 0001666071) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CDLX's EPS?
Cardlytics, Inc. has a diluted EPS of $-1.95.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.